(S)-4-benzyl-3-(2-(3-bromophenyl)acetyl)oxazolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-4-benzyl-3-(2-(3-bromophenyl)acetyl)oxazolidin-2-one
• 英文别名: (4S)-4-benzyl-3-[2-(3-bromophenyl)acetyl]-1,3-oxazolidin-2-one
• 化学式: C₁₈H₁₆BrNO₃
• 分子量: 374.234
• InChiKey: QKFKQBZNBAWXGG-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-4-benzyl-3-(2-(3-bromophenyl)acetyl)oxazolidin-2-one 在 双氧水 、 sodium hexamethyldisilazane 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 11.58h， 生成 (S)-2-(3-bromophenyl)propanoic acid
  参考文献：
  名称：

  [EN] MACROCYCLIC FACTOR VIIA INHIBITORS
  [FR] INHIBITEURS DU FACTEUR VIIA MACROCYCLIQUES

  摘要：

  公开号：

  WO2014201073A9
• 作为产物：
  描述：

  3-溴苯乙酸 、 (S)-4-苄基-2-唑烷酮 在 三甲基乙酰氯 、 N,N-二异丙基乙胺 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以81%的产率得到(S)-4-benzyl-3-(2-(3-bromophenyl)acetyl)oxazolidin-2-one
  参考文献：
  名称：

  Discovery of the first potent and selective αvβ5 integrin inhibitor based on an amide-containing core

  摘要：

  Integrins α_vβ₅ and α_vβ₃ are closely related, proangiogenic members of the wider RGD-binding integrin family. Due to their high sequence homology, the development of α_vβ₅-selective compounds has remained elusive to synthetic and medicinal chemists. Herein, we describe a survey of SAR around a series of amide-containing 3-aryl-succinamic acid-based RGD mimetics. This resulted in the discovery of α,α,α-trifluorotolyl 12 which exhibits 800 × selectivity for α_vβ₅versus α_vβ₃ with a pyrrolidine amide linker that confers selectivity for α_vβ₅ by positioning a key aryl ring in the SDL of α_vβ₅ with good complementarity; binding in this mode is disfavoured in α_vβ₃ due to clashes with key residues in the β₃-subunit. Compound 12 exhibits selective inhibition by a cell adhesion assay, high passive permeability and solubility which enables potential use of this inhibitor as an α_vβ₅-selective in vitro tool compound.

  DOI：

  10.1016/j.ejmech.2020.112719

文献信息

• A reagent based DOS strategy via Evans chiral auxiliary: highly stereoselective Michael reaction towards optically active quinolizidinones, piperidinones and pyrrolidinones
  作者：Subhabrata Sen、Siva R. Kamma、Rambabu Gundla、Uma Adepally、Santosh Kuncha、Sridhar Thirnathi、U. Viplava Prasad

  DOI：10.1039/c2ra22115b

  日期：——

  In the present study, we have demonstrated the diversity oriented synthesis of nitrogen heterocycles viz. chiral piperidinones, quinolizidinones and diaryl pyrrolidinones from Michael adducts generated via a TiCl4-catalyzed highly stereoselective Michael reaction with nitrostyrenes and an Evans chiral auxiliary. We also reported a Cu-4,4’-(isopropyl)-substituted isopropylidene-bridged 2,2’-bis-1,3’-oxazoline catalyst mediated catalytic asymmetric version of this reaction. In silico analysis is utilized to evaluate the diversity of the set of compounds against shape space (PMI), polar surface area (PSA) calculations and relevant drug like properties (viz. HBA, HBD, PSA, mol. wt., log P and log D). Finally, the molecules were screened against microorganisms to assess their antimicrobial properties.

  本研究中，我们展示了以多样性为导向的氮杂环合成，包括手性哌啶酮、喹诺利嗪酮和二芳基吡咯烷酮，这些氮杂环来自通过TiCl4催化的与硝基苯乙烯和对Evans手性辅基的高立体选择性迈克尔反应生成的迈克尔加合物。我们还报道了利用铜-4,4’-（异丙基）-取代异亚丙基桥联的2,2’-双-1,3’-噁唑啉催化剂介导的该反应的催化不对称版本。通过计算机模拟分析评估这一系列化合物的多样性，包括形状空间（PMI）、极性表面积（PSA）计算以及相关的似药性质（例如HBA、HBD、PSA、分子量、log P和log D）。最后，对这些分子进行了针对微生物的筛选，以评估它们的抗菌特性。
• MACROCYCLIC FACTOR VIIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160115159A1

  公开（公告）日：2016-04-28

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

  本发明提供了式（I）所定义的化合物和包含任何此类新型化合物的组合物。这些化合物是第VIIa因子抑制剂，可用作药物。
• Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent
  作者：Min-ah Kim、Jong Yup Kim、Kwang-Seop Song、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.tet.2007.10.056

  日期：2007.12

  Being obese has various health problems that are related to type 2 diabetes mellitus, cardiovascular disease, hypertension, hyperlipidemia, and fibrinolytic abnormalities. Merck's taranabant (MK-0364), a CB I R inverse agonist, is currently in Phase 3 clinical trials, and is being actively pursued by Merck toward obesity market. Merck intends to file for FDA approval of taranabant in 2008. In order to overcome practical difficulty involved in lab-scale preparation of taranabant with a dynamic kinetic resolution procedure developed by Merck's process group, we developed a 'user-friendly' method to install stereogenic centers by adopting Evans asymmetry chemistry. This method allowed us to prepare readily sub-gram scale of the target compound in a convenient way. (c) 2007 Elsevier Ltd. All rights reserved.
• Tetrahedron 2007, 63, 12845-12852
  作者：

  DOI：——

  日期：——
• US9657006B2
  申请人：——

  公开号：US9657006B2

  公开（公告）日：2017-05-23